The second batch of 40 varieties purchased with national capacity has been selected?!

The second batch of national procurement with volume, or the plan issued in June, implemented in October! ▍ more than 40 varieties have been selected, or a few days ago, there was news in the industry that the national procurement with volume will expand the results this year The specific implementing agency may have reported the idea and idea of "the second batch of purchasing plans and schemes with capacity will be issued in June this year and will be implemented in October" According to the news, the first batch of 4 + 7 will be fully implemented, and the second batch will be carried out in the middle and late March (i.e after the two sessions) It is reported that for the quantity of the second batch of varieties, there is a list of about 40 varieties, and the second batch can be purchased with quantity Maybe when it comes to the formal plan, the number should be more ▍ June or October? For this analysis, some well-known industry experts think it is "absolutely possible" He said that from the point of view of the goal of "achieving a significant reduction in drug prices; reducing transaction costs of enterprises, purifying the circulation environment and improving the industry ecology", the first batch of drugs has been achieved and there is no reason for the country not to expand the results of the war However, for the above implementation time node, some senior executives of a pharmaceutical company said that "it is said that the operation will start in June" The above analysis and prediction are only based on the policy trend of the industry, but one thing is the consensus of everyone that "the second batch will come sooner or later, it's only a matter of time" ▍ 18 drugs, which are likely to be selected into the second batch According to the statistics of cypress blue, up to now, 182 drugs have passed or are deemed to have passed the conformity evaluation of generic drugs, which provides a guarantee for the continuous carrying out of volume purchase From the perspective of data, according to the selection requirements of drugs purchased with quantity, one of the 18 varieties meets the requirements of many enterprises and has a large amount of drugs for clinical use, so it is more likely to be selected into the second batch of varieties purchased with quantity through comprehensive judgment They are ambroxol, acarbose, valsartan, voriconazole, metformin, clindamycin, moxifloxacin, repaglinide, glimepiride, azithromycin, temozonazole, cyclosporine, tamsulosin, amoxicillin, clarithromycin, bisoprolol, quetiapine, and bromfen ▍ another voice: it may not be so fast, but another analysis thinks that the volume purchase expansion will not be so fast First, there are not enough drugs passing the consistency evaluation at present; at the same time, after the announcement of the 4 + 7 election results, Shandong, Sichuan, Anhui, Fujian and other provinces once planned price linkage, but on January 9, Shandong Province, through the publicity of the consistency evaluation varieties on the Internet, did not see a significant decrease in the prices of 25 varieties of "4 + 7" This shows that in addition to 4 + 7 cities, the conditions for price reduction of selected drugs in other regions are not perfect, and it still needs a certain period of time After the pilot cities practice a complete set of perfect rules, large-scale linkage can be formed without market chaos Everbright Securities believes that it is still too early for the rapid extension of volume procurement in the three dimensions In the process of pilot implementation and summary of experience, the mode of volume procurement will be gradually improved, and the possibility of "increasing volume procurement, but no longer winning the bid exclusively at the lowest price" will not be ruled out in the future.